Synonyms: ADL 5747 | ADL-5747 | compound 36 [PMID: 19694468]
Compound class:
Synthetic organic
Comment: ADL5747 is a selective, nonpeptidic δ opioid receptor agonist [1]. Due to its favorable efficacy, safety, and pharmacokinetic profile ADL5747 was progressed as a clinical candidate for the treatment of pain.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
A Phase 2 clinical trial (NCT01058642) evaluating ADL5747's analgesic effect in patients with postherpetic neuralgia has been terminated. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01058642 | Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia | Phase 2 Interventional | Cubist Pharmaceuticals LLC |